Safety of Atypical Antipsychotics During Pregnancy

Current research indicates that the use of atypical antipsychotics during the first trimester of pregnancy is not associated with an increased risk of major congenital malformations. Studies, including the ongoing National Pregnancy Registry for Atypical Antipsychotics, suggest that these medications do not present a significant risk of teratogenicity. A large Japanese cohort study corroborates these findings, showing no notable pattern of malformations in women exposed to atypical antipsychotics. This data underscores that continuing treatment with these medications for pregnant women with serious psychiatric conditions, such as bipolar disorder, may be a prudent and safe choice.